ABCC7 p.Cys832Ala

ClinVar: c.2496C>A , p.Cys832* ? , not provided
Predicted by SNAP2: A: N (82%), D: N (57%), E: N (61%), F: N (72%), G: N (66%), H: N (78%), I: N (72%), K: N (66%), L: N (72%), M: N (66%), N: N (78%), P: N (53%), Q: N (78%), R: N (66%), S: N (78%), T: N (78%), V: N (87%), W: N (66%), Y: N (72%),
Predicted by PROVEAN: A: N, D: D, E: N, F: N, G: N, H: N, I: N, K: N, L: N, M: N, N: D, P: D, Q: N, R: N, S: N, T: N, V: N, W: N, Y: N,

[switch to compact view]
Comments [show]
Publications
[hide] Berger AL, Ikuma M, Welsh MJ
Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain.
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):455-60. Epub 2004 Dec 27., 2005-01-11 [PMID:15623556]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Wang W, Wu J, Bernard K, Li G, Wang G, Bevensee MO, Kirk KL
ATP-independent CFTR channel gating and allosteric modulation by phosphorylation.
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3888-93. Epub 2010 Feb 3., 2010-02-23 [PMID:20133716]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Wang G
State-dependent regulation of cystic fibrosis transmembrane conductance regulator (CFTR) gating by a high affinity Fe3+ bridge between the regulatory domain and cytoplasmic loop 3.
J Biol Chem. 2010 Dec 24;285(52):40438-47. Epub 2010 Oct 15., 2010-12-24 [PMID:20952391]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Cotten JF, Welsh MJ
Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator.
J Biol Chem. 1998 Nov 27;273(48):31873-9., 1998-11-27 [PMID:9822656]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Cotten JF, Welsh MJ
Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulator.
J Biol Chem. 1997 Oct 10;272(41):25617-22., [PMID:9325282]

Abstract [show]
Comments [show]
Sentences [show]